Clinical Trials Directory

Trials / Active Not Recruiting

Active Not RecruitingNCT07193147

Pharmacokinetic and Safety Study of GZR4 Injection in Subjects With Hepatic Impairment

A Single Dose Pharmacokinetic and Safety Study of GZR4 Injection in Subjects With Mild, Moderate, and Severe Hepatic Impairment and Normal Hepatic Function

Status
Active Not Recruiting
Phase
Phase 1
Study type
Interventional
Enrollment
36 (estimated)
Sponsor
Gan & Lee Pharmaceuticals. · Industry
Sex
All
Age
18 Years – 75 Years
Healthy volunteers
Accepted

Summary

This is a multicenter, single-dose, open-label, parallel Phase 1 clinical study to evaluate the PK profile, safety, and tolerability of GZR4 Injection in subjects with mild, moderate, and severe hepatic impairment.

Conditions

Interventions

TypeNameDescription
DRUGGZR4GZR4 s.c., single-dose

Timeline

Start date
2025-10-20
Primary completion
2026-07-14
Completion
2026-11-04
First posted
2025-09-25
Last updated
2025-11-28

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT07193147. Inclusion in this directory is not an endorsement.